D.S. Hong

2248P Integrated analysis of KRAS mutations and MTAP loss in pancreatic cancer reveals potential for combined blockade of KRAS and PRMT5

J. Rodon, Daria Yakimova, A. Kravets, Ksenia Kudriavtseva et autres

us (code pays fourni par la source)

WITHDRAWN: 2750eP Molecular tumor boards (MTB) as a tool for phase I and II clinical trial (CT) selection in sarcoma: A 5-year retrospective study

Chris Martin, Masanori Nakazawa, A.P. Conley, Abel Livingston et autres

us (code pays fourni par la source)

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors

Mohamed H. Derbala, Joud Hajjar, Bettzy Stephen, Serdar A. Gurses et autres

us (code pays fourni par la source)

New Cannabinoids and Chlorin-Type Metabolites from the Flowers of Cannabis sativa L.: A Study on Their Neuroblastoma Activity

Nguyễn Quốc Tuấn, D.S. Hong, Jae Hee Cheon, Young‐Mi Lee et autres

kr (code pays fourni par la source)

337 (PB325): Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations

Niamh Coleman, N.Y.L. Ngoi, Daniel Nguyen, B. Nelson et autres

Abstract P1-08-18: PIK/AKT/MTOR pathway activation in triple negative breast cancer and outcomes with matched therapy in phase I clinical trials: Response in both patients with and without direct molecular alterations

Prasanth Ganesan, SL Moulder, Filip Jankú, Aung Naing et autres

us (code pays fourni par la source)

246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors

Filip Jankú, D.S. Hong, Sheng Fu, Sarina A. Piha‐Paul et autres

253 Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors

Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, D.S. Hong et autres

366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase

Antonio Jimeno, Ronald Herbst, G. S. Falchook, Wells A. Messersmith et autres

Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer.

Ignacio Garrido‐Laguna, Filip Jankú, Apostolia M. Tsimberidou, J. J. Wheler et autres

Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor

Antonio Jimeno, D.S. Hong, Sally E Hecker, Robert Clément et autres

us (code pays fourni par la source)